Clinical Trial Update: Oxytocin Administration in BDD and OCD [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating oxytocin administration for body dysmorphic disorder and obsessive-compulsive disorder has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Body Dysmorphic Disorder
• Obsessive-compulsive Disorder

Drugs mentioned

• Oxytocin (Oxytocin)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Body Dysmorphic Disorder, Obsessive-compulsive Disorder | Phase 2 | Status: COMPLETED | Results posted: 2018-11-23